Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Cash flows from operating activities:
Net income (loss)	$ (23.0)	$ (103.9)
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:
Depreciation and amortization	56.5	18.9
Stock-based compensation expense	37.2	20.5
(Gain) loss from sale of investments, foreign currency and sale of assets, net	(9.0)	0.9
(Accretion) amortization on marketable debt securities, net		(1.9)
Noncash lease expense	4.2	4.2
Noncash interest expense	13.2	6.2
Change in deferred income taxes and other	(15.2)	5.4
Changes in operating assets and liabilities:
Accounts receivable, net	(59.5)	(27.3)
Prepaid expenses and other assets	(2.0)	1.4
Accounts payable	(18.8)	(9.0)
Deferred revenue	40.4	20.7
Income tax payable	5.9	2.5
Operating lease and other liabilities	(193.6)	26.2
Net cash provided by (used in) operating activities	(163.7)	(35.2)
Cash flows from investing activities:
Purchases of investments	(537.2)	(471.0)
Maturities of investments	83.9	605.4
Sales of investments		96.8
Acquisition of property and equipment	(1.7)	(8.5)
Business combinations, net of cash acquired	(19.6)
Asset acquisitions of intangible assets	(0.9)
Other investing activities, net	(0.3)	(1.0)
Net cash provided by (used in) investing activities	(475.8)	221.7
Cash flows from financing activities:
Debt issuance costs paid	(0.9)
Taxes paid related to net share settlement of stockholders' equity awards	(8.2)	(14.8)
Proceeds from issuance of common stock	10.5	8.8
Acquisition-related contingent consideration payments	(25.1)	(48.1)
Net cash provided by (used in) financing activities	(23.7)	(54.1)
Effect of exchange rate changes on cash, cash equivalents and restricted cash	(1.7)	(3.3)
Net change in cash, cash equivalents and restricted cash	(664.9)	129.1
Cash, cash equivalents and restricted cash, beginning of period	1,500.4	453.3
Cash, cash equivalents and restricted cash, end of period	835.5	$ 582.4
Noncash investing activity:
Acquisition-related deferred purchase consideration	$ 1.5